6-allyloxymethyl-3-(4-fluoro-phenyl)-2-(6-methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridine | 676344-55-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 6-allyloxymethyl-3-(4-fluoro-phenyl)-2-(6-methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridine
• 英文别名: 3-(4-fluorophenyl)-2-(6-methylpyridin-2-yl)-6-(prop-2-enoxymethyl)pyrazolo[1,5-a]pyridine
• CAS: 676344-55-1
• 化学式: C₂₃H₂₀FN₃O
• 分子量: 373.43
• InChiKey: CDLOOLMOOBPXRH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  39.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  [3-(4-fluoro-phenyl)-2-(6-methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-6-yl]-methanol 、 1-溴-3-氯丙烷 在 cesium carbonate 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 以27%的产率得到6-allyloxymethyl-3-(4-fluoro-phenyl)-2-(6-methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridine
  参考文献：
  名称：

  [EN] NOVEL PYRAZOLOPYRIDINE DERIVATVES AS PHARMACEUTICAL AGENTS
  [FR] DERIVES DE PYRAZOLOPYRIDINE TENANT LIEU D'AGENTS PHARMACEUTIQUES

  摘要：

  揭示了新型吡唑吡啶衍生物化合物及其作为药物代理的用途，特别是它们作为TGF-beta信号传导抑制剂在癌症和其他受TGF beta影响的疾病状态治疗中的用途。

  公开号：

  WO2004026871A1

文献信息

• Novel pyrazolopyridine derivatives as pharmaceutical agents
  申请人：Beight Wade Douglas

  公开号：US20050222197A1

  公开（公告）日：2005-10-06

  Novel pyrazolopyridine derivative compounds are disclosed and their use as pharmaceutical agents, in particular their use as TGF-beta signal transduction inhibitors useful in the treatment of cancer and other disease states influenced by TGF beta.

  本发明揭示了一种新型吡唑吡啶衍生物化合物，其作为药物代理使用，特别是其作为TGF-beta信号传导抑制剂在治疗癌症和其他受TGF beta影响的疾病状态中的应用。
• Pyrazolopyridine derivatives as pharmaceutical agents
  申请人：Eli Lilly and Company

  公开号：US07365066B2

  公开（公告）日：2008-04-29

  Novel pyrazolopyridine derivative compounds are disclosed and their use as pharmaceutical agents, in particular their use as TGF-beta signal transduction inhibitors useful in the treatment of cancer and other disease states influenced by TGF beta.

  本发明揭示了新型吡唑吡啶衍生物化合物，并且它们被用作制药剂，特别是用作TGF-beta信号传导抑制剂，可用于治疗受TGF beta影响的癌症和其他疾病状态。
• NOVEL PYRAZOLOPYRIDINE DERIVATIVES AS PHARMACEUTICAL AGENTS
  申请人：ELI LILLY AND COMPANY

  公开号：EP1543001A1

  公开（公告）日：2005-06-22
• PYRAZOLOPYRIDINE DERIVATIVES AS TGF BETA SIGNAL TRANSDUCTION INHIBITORS FOR THE TREATMENT OF CANCER
  申请人：ELI LILLY AND COMPANY

  公开号：EP1543001B1

  公开（公告）日：2007-08-15
• EFFICIENT INDUCTION OF PLURIPOTENT STEM CELLS USING SMALL MOLECULE COMPOUNDS
  申请人：Ichida Justin

  公开号：US20120021519A1

  公开（公告）日：2012-01-26

  The disclosure features a method of producing a reprogrammed cell (e.g. an induced pluripotent stem cell or an undifferentiated cell) from a differentiated (e.g. somatic) cell. In some embodiments, the methods includes contacting a differentiated (e.g. somatic cell) with a TGFBR1 inhibitor or anti-TGF-β-antibody to produce a reprogrammed cell (e.g. pluripotent stem cell or undifferentiated cell). Embodiments of the present invention relate to a reprogrammed cell and methods and compositions for producing a chemically produced reprogrammed cell or populations thereof.